Cargando…

An open, observational, three-arm clinical study of 2–3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis

BACKGROUND: An open, observational, three-arm clinical study aimed at investigating the efficacy of different neoadjuvant therapies (neoadjuvant immunotherapy with(out) chemotherapy, neoadjuvant chemotherapy, and neoadjuvant targeted therapy) in operable locally advanced non-small cell lung cancer (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Linping, Wang, Xue, Sun, Yile, Xu, Yunhua, Niu, Xiaomin, Zhao, Ruiying, Yao, Yaxian, Jian, Hong, Han, Yuchen, Wei, Jinwang, Chen, Zhiwei, Lu, Shun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437422/ https://www.ncbi.nlm.nih.gov/pubmed/36059450 http://dx.doi.org/10.3389/fimmu.2022.938269

Ejemplares similares

An open, observational clinical study of neoadjuvant therapy in resectable stage III non-small cell lung cancer
por: Qi, Yuwen, et al.
Publicado: (2023)

Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer
por: Shen, Jie, et al.
Publicado: (2023)

Desuccinylation of pyruvate kinase M2 by SIRT5 contributes to antioxidant response and tumor growth
por: Xiangyun, Ye, et al.
Publicado: (2016)

Integrative genomic analysis of drug resistance in MET exon 14 skipping lung cancer using patient-derived xenograft models
por: Xu, Yunhua, et al.
Publicado: (2022)

An inter-correlation among chemokine (C-X-C motif) ligand (CXCL) 1, CXCL2 and CXCL8, and their diversified potential as biomarkers for tumor features and survival profiles in non-small cell lung cancer patients
por: Gu, Linping, et al.
Publicado: (2021)

Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report
por: Gu, Linping, et al.
Publicado: (2022)

Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis
por: Thompson, Richard J., et al.
Publicado: (2023)

Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer
por: Wang, Xue, et al.
Publicado: (2021)

SMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers
por: Ji, Wenxiang, et al.
Publicado: (2022)

CapOX as neoadjuvant chemotherapy for locally advanced operable colon cancer patients: a prospective single-arm phase II trial
por: Liu, Fangqi, et al.
Publicado: (2016)

Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE)
por: Duan, Hongtao, et al.
Publicado: (2022)

Landscape and Predictive Significance of the Structural Classification of EGFR Mutations in Chinese NSCLCs: A Real-World Study
por: Gu, Linping, et al.
Publicado: (2022)

Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial
por: Chen, Dung-Tsa, et al.
Publicado: (2019)

Neoadjuvant Chemoradiotherapy for Oral Cavity Cancer: Predictive Factors for Response and Interim Analysis of the Prospective INVERT-Trial
por: von der Grün, Jens, et al.
Publicado: (2022)

Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study
por: Snijder, Berend, et al.
Publicado: (2017)

Limb-salvage operations in primary malignant tumors of the bone--interim report.
por: Lee, S. Y., et al.
Publicado: (1990)

Feasibility of semiquantitative 18F-fluorodeoxyglucose PET/computed tomography in patients with advanced lung cancer for interim treatment evaluation of combining immunotherapy and chemotherapy
por: Ke, Linping, et al.
Publicado: (2021)

Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma
por: Perrone, Anna Myriam, et al.
Publicado: (2023)

Adding Three Cycles of CAPOX after Neoadjuvant Chemoradiotherapy Increases the Rates of Complete Response for Locally Advanced Rectal Cancer
por: Zhai, Zhiwei, et al.
Publicado: (2021)

A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer
por: Hasegawa, Hirotaka, et al.
Publicado: (2022)

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
por: Chaft, Jamie E., et al.
Publicado: (2022)

Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients
por: Zhou, Zhen, et al.
Publicado: (2022)

Welcome with Open arms!
por: Simonds, Anita K.
Publicado: (2015)

Interim Report
por: SSC. Central Design Group. USA
Publicado: (1985)

Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial
por: Yang, Guozhen, et al.
Publicado: (2023)

Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial
por: Chen, Xiaofeng, et al.
Publicado: (2023)

Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study
por: Thiele, Elizabeth, et al.
Publicado: (2019)

The Value of (18)F-FDG PET/CT Imaging in the Evaluation of Interim Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer
por: Tatar, Gamze, et al.
Publicado: (2022)

Fourth Interim Report
por: Y. Blumenfeld and John Cornell
Publicado: (26/1)

Interim Design Report
por: Choubey, S., et al.
Publicado: (2011)

Structures - Interim Note
por: Sicard, C H
Publicado: (1983)

REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results
por: Olshansky, Brian, et al.
Publicado: (2020)

A multicenter, single-arm, open study of neoadjuvant or conversion atezolizumab in combination with chemotherapy in resectable small cell lung cancer (Cohort Study)
por: Duan, Hongtao, et al.
Publicado: (2023)

Operational Cycle
por: Solfaroli Camillocci, Matteo
Publicado: (2012)

Canaloplasty and Trabeculotomy Combined with Phacoemulsification in Open-Angle Glaucoma: Interim Results from the GEMINI Study
por: Gallardo, Mark J, et al.
Publicado: (2021)

The Effect of Crank Resistance on Arm Configuration and Muscle Activation Variances in Arm Cycling Movements
por: Mravcsik, Mariann, et al.
Publicado: (2021)

Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial
por: Jin, Jia, et al.
Publicado: (2022)

Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study
por: Chen, Zhiwei, et al.
Publicado: (2019)

Comprehensive molecular characterizations of stage I–III lung adenocarcinoma with tumor spread through air spaces
por: Ye, Ronghao, et al.
Publicado: (2023)

Transacsys PLC - Interim Results
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_e815gnmjn2gocdaptr965l84ec